2123. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken any review of whether the methodological assumptions applied in health technology assessments used in Ireland may disadvantage medicines intended to prevent long-term chronic illness by applying short-term modelling horizons; and if she will make a statement on the matter. [20315/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
2124. Deputy Ken O'Flynn asked the Minister for Health whether her Department intends to establish a national policy framework or guidance governing the methodological standards used in health technology assessments for medicines seeking reimbursement by the Health Service Executive, including standards relating to modelling time horizons for chronic disease prevention therapies; and if she will make a statement on t…
2177. Deputy Erin McGreehan asked the Minister for Health the specific steps the HSE is taking to ensure that the time critical and progressive nature of Friedreich's Ataxia is fully recognised and acted upon during the ongoing price and reimbursement negotiations for skyclarys, given the significant risk of irreversible decline for patients during prolonged delays. [20488/26]
2178. Deputy Erin McGreehan asked the Minister for Health the way in which the commitments outlined in the National Rare Disease Strategy 2025-2030 particularly those relating to timely access to innovative therapies are being applied in the case of skyclarys. [20489/26]
2179. Deputy Erin McGreehan asked the Minister for Health the way in which the 180 day decision timeline set out in the 2026 IPHA Framework Agreement is being implemented in practice for rare disease medicines; and the reason this timeline has not been met in the case of skyclarys for Friedreich's Ataxia patients. [20490/26]
2180. Deputy Erin McGreehan asked the Minister for Health whether her Department or the HSE has considered establishing an Early Access Programme for skyclarys, in light of the progressive and time sensitive nature of Friedreich's Ataxia, so that patients can access the treatment while reimbursement negotiations are ongoing. [20491/26]
2199. Deputy Maeve O'Connell asked the Minister for Health the position regarding the current reimbursement process for Omaveloxolone, considering the time-sensitive nature of the condition for those with Friedreich's ataxia; and if she will make a statement on the matter. [20597/26]
2219. Deputy Niall Collins asked the Minister for Health if she will ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for a progressive disease Friedreich's Ataxia (FA), which currently can be classed as having an ‘unmet need’, as outlined in the National Rare Disease Strategy 2025 – 2030; whether she believes the current delay ali…
2221. Deputy Aengus Ó Snodaigh asked the Minister for Health the reason access to Friedreich's Ataxia is not available on the medical card or licenced for the drug reimbursement scheme for patients in the State; and if she will make a statement on the matter. [20816/26]
2225. Deputy Cathal Crowe asked the Minister for Health the reason the HSE no longer provides funding for Novofine autocover needles; whether an alternative product will be considered for funding (details supplied); and if she will make a statement on the matter. [20860/26]
22. Deputy Peter Roche asked the Minister for Health if her Department has considered introducing an early access scheme for people living with rare diseases to access EMA-approved orphan medicines; if such an early access scheme will include orphan medicines products licensed for non-oncology conditions; and if she will make a statement on the matter. [17621/26]
35. Deputy Pádraig O'Sullivan asked the Minister for Health if she will provide an appraisal of the work that has been carried out on a review of the drugs reimbursement scheme and the creation of an early access scheme as per Programme for Government commitments; and if she will make a statement on the matter. [17474/26]
60. Deputy Peter Roche asked the Minister for Health when she intends to commence a review of the reimbursement process, as committed to in the Programme for Government; whether such a review will specifically include the way in which orphan medicines are assessed and reimbursed; and if she will make a statement on the matter. [17622/26]
75. Deputy Catherine Ardagh asked the Minister for Health her plans to expand access to weight loss medications given the health and societal costs of obesity; and if she will make a statement on the matter. [17500/26]
101. Deputy Aindrias Moynihan asked the Minister for Health the up-to-date position on a medication (details supplied) being available on the drugs payment scheme; and if she will make a statement on the matter. [17677/26]
119. Deputy Catherine Ardagh asked the Minister for Health her plans to review current regulations regarding the prescription of melatonin; and if she will make a statement on the matter. [17499/26]
120. Deputy Pádraig Rice asked the Minister for Health to provide an update on the delivery of the programme for Government commitment to continue to extend access to free contraception; the work carried out to date; the timeline she is working towards in expanding the scheme; and if she will make a statement on the matter. [17723/26]
525. Deputy Conor Sheehan asked the Minister for Health the specific steps being taken to ensure the HSE considers the time-critical nature of Friedreich’s ataxia during the current price negotiations for Skyclarys, the only drug approved for treatment of this condition, given the 570 days since the application for use was lodged and the rapid progression of the disease in sufferers; and if she will make a statement …
526. Deputy Conor Sheehan asked the Minister for Health the way in which the commitments in the National Rare Disease Strategy 2025 – 2030 are being applied to the approval process for the drug Skyclarys used to treat Friedrich's ataxia to prevent further delays in addressing the unmet need of sufferers; and if she will make a statement on the matter. [17918/26]
527. Deputy Conor Sheehan asked the Minister for Health the way in which the 2026 IPHA Framework Agreement on access to new and innovative medicines which aims for a 180-day decision timeline is being applied to the drug Skyclarys used to treat Friedrich's ataxia to prevent further delays in addressing the unmet need of sufferers; and if she will make a statement on the matter. [17919/26]
538. Deputy Alan Kelly asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which currently can be classed as having an ‘unmet need’ as outlined in the National Rare Disease Strategy 2025 – 2030; and if she will make a statement on the matter. [17958/2…
539. Deputy Alan Kelly asked the Minister for Health her views on whether the current delay regarding the Skyclarys reimbursement negotiations aligns with the "equitable access" promised in the newly launched National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [17959/26]
569. Deputy Donna McGettigan asked the Minister for Health to make acarizax available under the drug payment scheme; to recommend a course of action for a family facing unmanageable prescription charges due to having to pay for it, in addition to other medications which are on the drug payment scheme, but still cost €80; and if she will make a statement on the matter. [18051/26]
590. Deputy Charles Ward asked the Minister for Health whether a chairperson has been assigned to the cannabis access review panel; if so, whether the Minister could advise the person chosen; if not, when will this position be filled so that work on the review can be commenced; and if she will make a statement on the matter. [18163/26]
248. Deputy William Aird asked the Minister for Health if she will include acarizax on the reimbursement list of medicines; and if she will make a statement on the matter. [17270/26]